48. 原発性抗リン脂質抗体症候群 Primary antiphospholipid syndrome Clinical trials / Disease details

臨床試験数 : 4 / 薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05078710 (ClinicalTrials.gov)	July 1, 2021	24/9/2021	Telitacicept in Primary APS Patients	A Pilot Study of Telitacicept Treatment in Primary APS Patients	Anti Phospholipid Syndrome	Drug: Telitacicept	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	65 Years	All	20	Phase 2	China
2	NCT03540810 (ClinicalTrials.gov)	August 15, 2018	27/4/2018	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome	Primary Antiphospholipid Syndrome	Drug: Hydroxychloroquine;Drug: Placebo	University Hospital, Angers	NULL	Not yet recruiting	18 Years	N/A	All	300	Phase 3	France
3	NCT01956188 (ClinicalTrials.gov)	May 2014	25/9/2013	Omega 3 in LES and APS	Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome	Systemic Lupus Erythematosus;Primary Antiphospholipid Syndrome	Dietary Supplement: EPA and DHA supplementation;Dietary Supplement: Placebo	University of Sao Paulo	NULL	Active, not recruiting	20 Years	45 Years	Female	22	N/A	Brazil
4	NCT04153201 (ClinicalTrials.gov)	January 15, 2013	21/10/2019	Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome	Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study.	Antiphospholipid Syndrome	Drug: Hydroxychloroquine	National and Kapodistrian University of Athens	NULL	Completed	18 Years	N/A	All	50	N/A	Greece